QRG Capital Management Inc. Acquires 49,804 Shares of Pfizer Inc. $PFE

QRG Capital Management Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 5.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 902,308 shares of the biopharmaceutical company’s stock after buying an additional 49,804 shares during the period. QRG Capital Management Inc.’s holdings in Pfizer were worth $21,728,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Vermillion Wealth Management Inc. boosted its stake in Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the last quarter. Eagle Capital Management LLC lifted its holdings in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares in the last quarter. Delta Financial Advisors LLC boosted its position in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the last quarter. Pines Wealth Management LLC grew its holdings in Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 400 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD raised its position in Pfizer by 1.0% in the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 400 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer CEO Albert Bourla purchased approximately $1 million of company stock, adding 38,000 shares. The insider purchase may signal management’s confidence that the shares are undervalued. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer’s second-quarter results exceeded expectations, and management modestly raised 2026 revenue guidance to $60.5 billion-$62.5 billion. Analysts also highlighted stable core operations, strength from acquired brands and recent launches, and momentum in the non-COVID business. 5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
• Positive Sentiment: Positive Phase 3 results for LITFULO in nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s effort to replace declining COVID-related revenue with newer products. Pfizer’s Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Recent coverage points to growing investor interest in Pfizer’s launches, acquisitions and pipeline as potential drivers of longer-term growth, particularly from 2029 onward. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
• Neutral Sentiment: Analysts remain broadly focused on Pfizer’s valuation and earnings outlook; Erste Group raised its 2026 EPS estimate to $2.95 from $2.92, close to the approximately $2.98 consensus. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Pfizer discontinued hemophilia gene therapy BEQVEZ as the commercial market contracts and physicians demand longer-term efficacy data, removing a potential growth contributor. Gene Therapy Remains Top-of-Mind in Hemophilia
• Negative Sentiment: Pfizer agreed to a $44 million class-action settlement related to Chantix safety-disclosure claims. The financial charge is manageable relative to Pfizer’s size but highlights continuing litigation exposure. Pfizer Agreed to a $44 Million Chantix Settlement
• Negative Sentiment: Arbutus filed additional patent-enforcement lawsuits against Pfizer and BioNTech concerning lipid nanoparticle technology, creating another potential legal overhang tied to COVID vaccine intellectual property. Arbutus Reports Second-Quarter Results

Analysts Set New Price Targets

A number of research firms have issued reports on PFE. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 1.9%

PFE opened at $26.80 on Friday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company’s 50-day moving average price is $25.11 and its two-hundred day moving average price is $26.19. The stock has a market cap of $152.77 billion, a price-to-earnings ratio of 35.27 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s payout ratio is presently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.